A promising ALS drug may help combat glioblastoma by targeting the cancerous stem cells that fuel tumor growth.

Glioblastoma is the most common and aggressive type of primary brain tumor, with an average survival rate of 15 months, ...

The Glioblastoma Research Organization (GBMRO), a nonprofit organization raising awareness and funds for cutting-edge research to find a cure for glioblastoma, is hosting its inaugural Glioblastoma ...

Glioblastoma is the most common – and the most malignant – primary brain tumor in adults. It's aggressive and incurable.

A new study shows the potential power of imaging paired with radiation to shape treatment for glioblastoma patients in real time. The study, led by researchers at Sylvester Comprehensive Cancer Center ...

In a small but important Phase 1 study, MTX110 is outperforming historic norms of progression free and overall ...

The agent is currently being evaluated in a phase 1a study, and a phase 1b/2a study will continue to assess LP-184’s safety ...

Shilpa Medicare's drug is presently undergoing a Phase 1A clinical trial to test its safety and how well it is tolerated in ...

A Florida court blocked Monday Gov. DeSantis' effort to stop abortion rights TV ads as the legal battle over Amendment 4 ...

Violets' cyclotides could revolutionize glioblastoma treatment by boosting chemotherapy efficacy, now advancing to mouse ...

Developed by AI, Lantern Pharma's investigational drug LP-184 has received FDA Fast-Track Designation for glioblastoma.

A personalised vaccine for the aggressive and fatal brain cancer glioblastoma has shown encouraging signs of efficacy in its first human trial. The vaccine – developed by researchers at the ...